The FURVENT miss removes the most advanced catalyst for firmonertinib's U.S. approval path in first-line EGFR exon 20 NSCLC. Watch for the company's updated development strategy and potential pipeline reprioritization, including the ongoing ALPACCA Phase 3 trial in EGFR PACC mutations.
Price Chart
Executive Summary
ArriVent announced that its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC did not meet the primary endpoint of progression-free survival by BICR. The 240mg arm showed a median PFS of 11.0 months vs 9.5 months for control (HR 0.75, p=0.0654), missing statistical significance. The company is evaluating the full dataset to determine the development path for firmonertinib, its lead candidate.
Key Facts
- Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC did not meet primary endpoint of PFS by BICR
- 240mg arm median PFS 11.0 months vs control 9.5 months (HR 0.75, 95% CI 0.55-1.02, p=0.0654)
- 160mg arm median PFS 8.4 months vs control 9.5 months (HR 0.91, 95% CI 0.67-1.25)
- Confirmed ORR by BICR: 60% for 240mg, 35% for 160mg, 33% for control
- Safety profile consistent with prior studies; Grade ≥3 TEAEs 52% (240mg), 53% (160mg), 55% (control)
- Study enrolled 398 patients globally; firmonertinib had FDA Breakthrough Therapy Designation for this indication
- Company evaluating full dataset to determine appropriate development path for firmonertinib
Financial Impact
Phase 3 failure of lead pipeline candidate firmonertinib in a pivotal first-line indication; no financial figures provided in filing
Risk Factors
- Regulatory path for firmonertinib in first-line U.S. indication is now uncertain
- Potential need for additional trials or combination strategies to salvage the program
- Cash runway and resource allocation may be impacted if lead program is deprioritized
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-113898 |
| Document: tm2627092d1_ex99-1.htm | 0001104659-26-113898 |
| Document: 0001104659-26-113898-index-headers.html | 0001104659-26-113898 |
| Document: 0001104659-26-113898-index.html | 0001104659-26-113898 |
| Document: 0001104659-26-113898.txt | 0001104659-26-113898 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $23.64 | awaiting T+5 | — | $15.69 (−33.63%) |
Oct 25, 2026 1d ago | Press Release | $21.00 | awaiting T+5 | — | $15.69 (−25.29%) |
Oct 23, 2026 2d ago | Press Release | $21.00 | awaiting T+5 | — | $15.69 (−25.29%) |
Oct 19, 2026 7d ago | 8-K | $17.94 | awaiting T+5 | — | $15.69 (−12.54%) |
Oct 13, 2026 12d ago | SC 13G | $16.20 $19.12 | ▲ +18.02% | ▲ +17.57% | $15.69 (−3.15%) |
Oct 13, 2026 13d ago | 8-K | $16.09 $18.85 | ▲ +17.15% | ▲ +18.31% | $15.69 (−2.49%) |
Oct 8, 2026 17d ago | SC 13D/A | $16.73 $16.66 | ▲ +0.42% | ▼ −1.55% | $15.69 (+6.22%) |
Oct 6, 2026 20d ago | 8-K | $15.09 $16.09 | ▼ −6.63% | ▼ −6.77% | $15.69 (−3.98%) |
Aug 12, 2026 10w ago | Press Release | $30.00 $29.18 | ▲ +2.73% | ▲ +0.77% | $15.69 (+47.70%) |
Jun 11, 2026 19w ago | Institutional Cluster | $30.54 $31.74 | ▲ +3.93% | ▲ +3.26% | $15.69 (−48.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers